E. J. Gane Et Al. , "FACTORS ASSOCIATED WITH A LACK OF VIRAL SUPPRESSION IN CHRONIC HBV ( CHB) PATIENTS AFTER 8 YEARS OF TREATMENT WITH TENOFOVIR ALAFENAMIDE ( TAF) OR TENOFOVIR DISOPROXIL FUMARATE ( TDF) FOLLOWED BY TAF TREATMENT," Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , Massachusetts, United States Of America, 2023
Gane, E. J. Et Al. 2023. FACTORS ASSOCIATED WITH A LACK OF VIRAL SUPPRESSION IN CHRONIC HBV ( CHB) PATIENTS AFTER 8 YEARS OF TREATMENT WITH TENOFOVIR ALAFENAMIDE ( TAF) OR TENOFOVIR DISOPROXIL FUMARATE ( TDF) FOLLOWED BY TAF TREATMENT. Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , (Massachusetts, United States Of America).
Gane, E. J., Buti, M., Fung, S. K., Chan, H. L. Y., Izumi, N., Chuang, W. L., ... Ahn, S. H.(2023). FACTORS ASSOCIATED WITH A LACK OF VIRAL SUPPRESSION IN CHRONIC HBV ( CHB) PATIENTS AFTER 8 YEARS OF TREATMENT WITH TENOFOVIR ALAFENAMIDE ( TAF) OR TENOFOVIR DISOPROXIL FUMARATE ( TDF) FOLLOWED BY TAF TREATMENT . Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America
Gane, Edward Et Al. "FACTORS ASSOCIATED WITH A LACK OF VIRAL SUPPRESSION IN CHRONIC HBV ( CHB) PATIENTS AFTER 8 YEARS OF TREATMENT WITH TENOFOVIR ALAFENAMIDE ( TAF) OR TENOFOVIR DISOPROXIL FUMARATE ( TDF) FOLLOWED BY TAF TREATMENT," Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 2023
Gane, Edward J. Et Al. "FACTORS ASSOCIATED WITH A LACK OF VIRAL SUPPRESSION IN CHRONIC HBV ( CHB) PATIENTS AFTER 8 YEARS OF TREATMENT WITH TENOFOVIR ALAFENAMIDE ( TAF) OR TENOFOVIR DISOPROXIL FUMARATE ( TDF) FOLLOWED BY TAF TREATMENT." Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , Massachusetts, United States Of America, 2023
Gane, E. J. Et Al. (2023) . "FACTORS ASSOCIATED WITH A LACK OF VIRAL SUPPRESSION IN CHRONIC HBV ( CHB) PATIENTS AFTER 8 YEARS OF TREATMENT WITH TENOFOVIR ALAFENAMIDE ( TAF) OR TENOFOVIR DISOPROXIL FUMARATE ( TDF) FOLLOWED BY TAF TREATMENT." Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , Massachusetts, United States Of America.
@conferencepaper{conferencepaper, author={Edward J. Gane Et Al. }, title={FACTORS ASSOCIATED WITH A LACK OF VIRAL SUPPRESSION IN CHRONIC HBV ( CHB) PATIENTS AFTER 8 YEARS OF TREATMENT WITH TENOFOVIR ALAFENAMIDE ( TAF) OR TENOFOVIR DISOPROXIL FUMARATE ( TDF) FOLLOWED BY TAF TREATMENT}, congress name={Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)}, city={Massachusetts}, country={United States Of America}, year={2023}}